Instructions for Obtaining Category 1 CME Credits : The Endocrinologist

Journal Logo

You can read the full text of this article if you:

Access through Ovid
00019616-200803000-00014MiscellaneousThe EndocrinologistThe Endocrinologist© 2008 Lippincott Williams & Wilkins, Inc.18March 2008 p 101-105Instructions for Obtaining Category 1 CME CreditsContinuing Medical EducationSix individual CME activities are available through the journal each year.Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.Lippincott Continuing Medical Education Institute, Inc. designates this educational activity for a maximum of three (3) AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.An annual total of 18 AMA PRA Category 1 Credits™ are available through the six 2008 issues of The Endocrinologist.This CME activity is intended for endocrinologists and other health care professionals with an interest in the diagnosis and management of endocrine-related disorders.The treatment of the endocrine system is a complex and multi-tiered process in which the physician must correctly diagnose the disorder, select the appropriate course of treatment, and restore an optimal level of disease-free function. To that end, endocrinologists have expressed a desire for increased knowledge of the function and pathology of all areas of endocrinology, including adrenal, bone and mineral, diabetes, growth and development, lipids and metabolism, neuroendocrinology, reproduction, and thyroid. Rapid advances in our understanding of the diseases and conditions of the endocrine system, particularly as those advances relate to the clinical environment, make it difficult for the busy practicing physician to keep abreast of important information.The Endocrinologist is an established, peer-reviewed journal designed to meet the needs of the practicing endocrinologist. Each year the Editor-in-Chief conducts a literature search to ascertain topics that will be of greatest interest and most benefit to our readers. The journal is intended to address the concerns challenging today's practitioners, to create a forum for setting standards of care, and to establish a network with the highest levels of expertise in the field.The Editor-in-Chief of The Endocrinologist, Lynn D. Loriaux, M.D., Ph.D., is a world renowned expert in endocrinology and is past president of the Endocrine Society. He has developed an editorial board of nationally and internationally recognized physicians to assist him in selecting and evaluating articles for publication.The format and design of The Endocrinologist will allow it to serve as a creditable and effective distance learning tool for physicians interested in refining their problem-solving skills, learning about the most recent advances in the field, and applying these advances to patient care.Learning objectives for each CME activity are procured and printed before each CME article in each issue.Article author credentials and financial disclosure information are procured and printed in each CME article in each issue.Between two and four articles published in each bi-monthly issue will be designated course reading. Those who are interested in earning CME credit for individual issues should read each article and then complete the examination included in the issue. The tuition for each issue's CME activity is US$20.To earn CME credit, you must read the designated CME articles in that issue and complete that issue's examination and evaluation assessment questionnaire, answering at least 70% of the examination questions correctly. Mail a photocopy of the completed page along with a check for US$20 payable to Lippincott Continuing Medical Education Institute, Inc. to:Lippincott Continuing Medical Education Institute, Inc., 770 Township Line Road, Suite 300, Yardley, PA 19067Only the first entry will be considered for credit and must be received by LCMEI by the expiration date stated in each issue. Acknowledgment will be sent to you within four to six weeks of participation.For more information about this CME program, please contact James T. Magrann, Executive Director of Continuing Education, Lippincott Continuing Medical Education Institute, Inc., 770 Township Line Road, Suite 300, Yardley, PA 19067; Phone: 267-757-3536; Fax: 267-757-0651.The Endocrinologist CME Examination March/April 2008: Expiration Date/Postmark Deadline: October 31, 2008Please mark your answers on the Answer Sheet.Review Article 4–Mechanisms of Hypothalamic-Pituitary Injury After Oncologic Disease1. Which of the following statements relating brain tumors and their treatment to hypothalamic and pituitary injury is correct?A. The pituitary gland is more sensitive to injury from irradiation than is the hypothalamus.B. In contrast to young children, radiotherapy does not lead to hypopituitarism in adults.C. Pituitary responsiveness to releasing hormones may continue to decline more than 10 years after cranial irradiation.D. In the absence of brain tumor or cranial irradiation, chemotherapy does not alter hypothalamic-pituitary function.2. The rate of decline in peak growth hormone levels in children having cranial irradiation is influenced byA. The radiation dose to the hypothalamus.B. The presence or absence of hydrocephalus.C. The tumor site.D. All of these.E. None of these.3. In each of two proposed sequences of hypothalamic pituitary deficiencies following irradiation for intracranial tumor, the initial deficiency involvesA. Thyroid-stimulating hormone.B. Growth hormone.C. Adrenocorticotropin.4. Which of these alternative radiotherapy techniques is able to lower radiation doses to the optic chiasm, pituitary gland, and uninvolved tissues; conform closely to target volumes; utilize steep dose gradients; and spare normal tissue?A. Stereotactic radiosurgery.B. Intensity-modulated radiotherapy.C. Proton beam radiation.5. In order to detect hypothalamic-pituitary injury after cancer treatment by cranial irradiation or chemotherapy, hypothalamic and pituitary function should be monitored for at leastA. 12 months.B. 2 years.C. 5 years.D. 10 years.Review Article 5–Phenotypic Expression and Challenges of a Distinct Form of Thyrotoxicosis: Triiodothyronine-Predominant Graves Disease—Aggressive, Refractory, and Anything but Banal6. This patient presented withA. Palpable thyroid nodules.B. A massive diffuse goiter accompanied by a bruit.C. Evidence of retrosternal extension.D. Pretibial myxedema.E. Signs of Graves orbitopathy.7. This patient regained normal thyroid function in response toA. Methimazole in doses as high as 30 mg daily.B. Multiple courses of carbimazole.C. Three preoperative doses of radioiodine.D. Total thyroidectomy.E. A fourth, post-thyroidectomy dose of radioiodine.8. Triiodothyronine (T3)-predominant Graves disease is found in approximately ___ of thyrotoxic patients.A. 1%B. 2%C. 5%D. 10%E. 25%9. Available evidence suggests that T3-predominant Graves disease may result fromA. Decreased 5′deiodinase activity.B. A reduced ratio of T3 to thyroxine in thyroglobulin before hydrolysis.C. Decreased intra-thyroidal iodine content.10. Typically, patients with T3-predominant Graves thyrotoxicosis ___ spontaneous remission after multiple courses of anti-thyroid drug treatment or radioiodine therapy.A. achieveB. do not achieveReview Article 6–Cyclical Cushing's Disease Due to Bronchial Carcinoid: Early Diagnosis and Prompt Treatment11. The presenting clinical features in this patient included all of the following exceptA. Weight loss.B. Numbness of the extremities.C. Muscle weakness.D. Hirsutism.E. Hypertension.12. The results of a ___ most strongly suggested a non-pituitary origin of ACTH secretion.A. low-dose dexamethasone testB. high-dose dexamethasone testC. corticotropin-releasing hormone stimulation test13. Surgical removal from this patient of a bronchial carcinoid tumor that stained for ACTH resulted inA. No substantial change in clinical status.B. Slight improvement.C. Moderate improvement.D. Complete cure.14. An ACTH-secreting pituitary adenoma ___ cyclical Cushing's disease.A. is a rare cause ofB. causes a minority of cases ofC. causes a majority of cases ofD. accounts for virtually all cases of15. Following removal of a bronchial carcinoid that caused cyclical Cushing's disease, routine postoperative steroid supplementationA. Is always necessary.B. Is never necessary.C. May not be necessary.The Endocrinologist CME Examination: EXAMINATION ANSWER SHEETJOURNAL/endst/04.03/00019616-200803000-00014/figure1-14/v/2021-02-17T201845Z/r/image-tiffNo caption available.Evaluation Form March/April 2008JOURNAL/endst/04.03/00019616-200803000-00014/figure2-14/v/2021-02-17T201845Z/r/image-tiffNo caption available.Instructions for Obtaining Category 1 CME CreditsContinuing Medical EducationContinuing Medical Education218p 101-105